Drug Profile
ASP 1128
Alternative Names: ASP-1128; MA-0217; MTB-2Latest Information Update: 06 May 2022
Price :
$50
*
At a glance
- Originator Mitobridge
- Developer Astellas Pharma
- Class Small molecules; Urologics
- Mechanism of Action Peroxisome proliferator-activated receptor delta modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute kidney injury
Most Recent Events
- 06 May 2022 Discontinued - Phase-II for Acute kidney injury in USA (IV) (Astellas Pharma pipeline, May 2022)
- 20 Oct 2021 Astellas Pharma completes a phase II trial in Acute kidney injury in USA (NCT03941483)
- 05 Mar 2021 Phase-II development for Acute kidney injury is ongoing in the US (NCT03941483)